Dr Tao Liu obtained his PhD from The University of New South Wales Sydney, Australia, in 2000. He then worked as a post-doc with Professor Samuel Breit at St. Vincent's Centre for Applied Medical Research Sydney and Professor Glenn Marshall at Children’s Cancer Institute Australia. He is now Head of Histone Modification Group at Children’s Cancer Institute Australia, and an Australian Research Council Future Fellow at The University of New South Wales. In the last 5 years, Dr. Liu has been working on the roles of long noncoding RNAs, histone methyltransferases, histone deacetylases and BET bromodomain proteins in modulating gene transcription, N-Myc-regulated malignant transformation, neuroblastoma initiation and progression in vitro and in vivo, as well as the anticancer efficacy of antisense oligonucleotides targeting long noncoding RNAs, histone methyltransferase inhibitors, histone deacetylase inhibitors and BET bromodomain inhibitors in vitro and in vivo.
Abstracts this author is presenting: